Skip to main content

Table 4 Causes of infliximab discontinuation in ATIpos and ATIneg patientsa

From: Antibodies toward infliximab are associated with low infliximab concentration at treatment initiation and poor infliximab maintenance in rheumatic diseases

Cause of discontinuation ATIpos (n= 18) ATIneg (n= 41)
Treatment failure   
   Primary failure 2 (11%) 23 (56%)
   Secondary failure 3 (17%) 8 (20%)
Infusion reactions 9 (50%) 1 (2%)
Adverse events 1 (5.5%) 6 (15%)
Other 1 (5.5%) 2 (5%)
Lost to follow-up 2 (11%) 1 (2%)
  1. aATI: antibodies toward infliximab; ATIpos: ATI detected at least once during follow-up; ATIneg: ATI not detected. All data are number of patients (%).